Pfizer Inc. has announced results from the Phase 3 THRIVE-131 study, which evaluated inclacumab, an investigational P-selectin inhibitor, in patients aged 16 and older with sickle cell disease. The study did not achieve its primary endpoint of a significant reduction in the rate of vaso-occlusive crises in participants receiving inclacumab compared to a placebo over a 48-week period. Inclacumab was generally well tolerated, with common adverse events including anemia, arthralgia, back pain, headache, malaria, sickle cell anemia with crisis, and upper respiratory tract infection. Pfizer remains committed to the sickle cell community and plans to share detailed analyses of the data with the scientific and patient community in due course. In addition, the company is progressing with its broader sickle cell disease portfolio, including OXBRYTA® (voxelotor) and osivelotor, with updates to be provided as they become available.